Gubra A/S (CPH:GUBRA)
431.60
+4.00 (0.94%)
Nov 4, 2025, 4:59 PM CET
Gubra Revenue
Gubra had revenue of 2.49B DKK in the half year ending June 30, 2025, with 2,347.66% growth. This brings the company's revenue in the last twelve months to 2.64B, up 1,078.32% year-over-year. In the year 2024, Gubra had annual revenue of 265.74M with 29.63% growth.
Revenue (ttm)
2.64B
Revenue Growth
+1,078.32%
P/S Ratio
2.67
Revenue / Employee
9.59M
Employees
260
Market Cap
7.05B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 265.74M | 60.74M | 29.63% |
| Dec 31, 2023 | 205.01M | 5.62M | 2.82% |
| Dec 31, 2022 | 199.38M | -55.95M | -21.91% |
| Dec 31, 2021 | 255.33M | 83.03M | 48.19% |
| Dec 31, 2020 | 172.30M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk | 311.94B |
| Coloplast | 27.87B |
| H. Lundbeck | 23.52B |
| Genmab | 23.16B |
| Demant | 22.59B |
| GN Store Nord | 17.33B |
| Zealand Pharma | 9.11B |
| Bavarian Nordic | 6.46B |
Gubra News
- 5 months ago - Gubra’s Innovation in Peptide-Based Drug Discovery - Nasdaq
- 8 months ago - Healthy Returns: AbbVie is the newest potential weight loss drug market player - CNBC
- 8 months ago - AbbVie Steps Into The Ring In The Obesity Drug Wars - Seeking Alpha
- 8 months ago - AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race - Benzinga
- 8 months ago - AbbVie Joins Obesity Treatment Market With Up to $2.2B Licensing Deal - Investopedia
- 8 months ago - AbbVie (ABBV) Enters Weight Loss Market with $2.2 Billion Gubra Deal - GuruFocus
- 8 months ago - AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. - Investor's Business Daily
- 8 months ago - AbbVie forays into obesity market with up to $2.2B Gubra license deal - Seeking Alpha